Filing Details
- Accession Number:
- 0000899243-21-044648
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-15 18:52:09
- Reporting Period:
- 2021-11-15
- Accepted Time:
- 2021-11-15 18:52:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1851657 | Vaxxinity Inc. | VAXX | Pharmaceutical Preparations (2834) | 862083865 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1890672 | Ulo Palm | C/O Vaxxinity, Inc. 1717 Main St, Ste 3388 Dallas TX 75201 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2021-11-15 | 450 | $13.00 | 450 | No | 4 | P | Indirect | Held by spouse |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | Held by spouse |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Class A Common Stock | Stock option (right to buy) | Acquisiton | 2021-11-11 | 233,100 | $0.00 | 233,100 | $13.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
233,100 | 2031-11-11 | No | 4 | A | Direct |
Footnotes
- These securities were purchased through the Issuer's directed share program in connection with its initial public offering.
- These securities are held by Kathrin Palm, the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by Kathrin Palm in which the Reporting Person has no pecuniary interest.
- These options are subject to a four-year time-vesting schedule, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal installments each month during the remainder of the vesting period.